Inside the research
ANI Pharmaceuticals, Inc.
ANIP Research profile · latest available data
Price overview
$74.00
▼ -0.04 (-0.1%)
| 52w hi | $95.38 |
|---|---|
| 52w lo | $70.19 |
| Vol | 278.70K |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.02
| Short | -0.45 |
|---|---|
| Medium | +0.09 |
| Long | +0.63 |
computed 2026-09-27
Key fundamentals
ANI Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
| Market cap | $1.70B |
|---|---|
| Enterprise value | $1.83B |
| Trailing P/E | 16.19x |
| Forward P/E | 7.06x |
| EV / EBITDA | 8.76x |
| P / S (ttm) | 1.74x |
| Profit margin | 11.1% |
| Return on equity | 20.5% |
| Revenue growth | +25.9% |
| Earnings growth | +191.1% |
| Debt / equity | 104.83 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.44 | |
| Sector | +0.08 | |
| Technical | -0.27 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Risk Metrics
| Beta vs SPX | 0.56 |
|---|---|
| Corr SPX | 0.25 |
| Annual vol | 35.3% |
| Annual ret | +16.9% |
| Sharpe | 0.48 |
| Max DD | -29.0% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $110.62 |
|---|---|
| High / Low | $124.00 / $90.00 |
| Median | $113.00 |
| Analysts | 8 |
| Strong Buy | 3 | |
|---|---|---|
| Buy | 4 | |
| Hold | 1 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-01-16 | Guggenheim | → Buy |
| 2025-12-09 | Barclays | → Overweight |
| 2025-11-10 | Guggenheim | → Buy |
| 2025-10-09 | Truist Securities | → Hold |
| 2025-09-24 | JP Morgan | → Overweight |
| 2025-09-17 | HC Wainwright & Co. | → Buy |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-07 | Earnings Release, Reg FD Disclosure… | read |
| 2026-05-21 | Officer / Director Change, Shareholder Vote… | read |
| 2026-05-13 | Reg FD Disclosure, Exhibits | read |
| 2026-05-08 | Earnings Release, Exhibits | read |
| 2026-04-07 | Auditor Change, Exhibits | read |
| 2026-03-03 | Reg FD Disclosure, Exhibits | read |
| 2026-02-27 | Earnings Release, Exhibits | read |
| 2026-01-12 | Earnings Release, Reg FD Disclosure… | read |
| 2025-12-01 | Officer / Director Change, Reg FD Disclosure… | read |
| 2025-11-10 | Earnings Release, Reg FD Disclosure… | read |
| 2025-11-07 | Earnings Release, Exhibits | read |
| 2025-09-26 | Securities Issuance, 3.03 | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & | Sell | 500 | $37.74K |
| 2026-08-10 | Gutwerg Ori | SVP, GENERICS | Sell | 3.16K | $243.47K |
| 2026-07-29 | CAREY STEPHEN P. | SVP & CFO | Sell | 2.85K | $231.88K |
| 2026-07-18 | Cook Meredith | SR. VP, GENERAL COUNSEL & | Withheld for tax | 2.47K | $195.31K |
| 2026-07-13 | Cook Meredith | SR. VP, GENERAL COUNSEL & | Sell | 500 | $40.92K |
| 2026-07-02 | CAREY STEPHEN P. | SVP & CFO | Option exercise | 3.31K | $164.03K |
| 2026-07-02 | CAREY STEPHEN P. | SVP & CFO | Sell | 3.31K | $284.92K |
| 2026-06-29 | CAREY STEPHEN P. | SVP & CFO | Sell | 2.85K | $239.74K |
| 2026-06-12 | Cook Meredith | SR. VP, GENERAL COUNSEL & | Sell | 500 | $41.02K |
| 2026-05-21 | Thoma Jeanne | Grant | 4.36K | — |
Flow & Concentration
| Insider 180d net | -$1.12M |
|---|---|
| Insider buys / sells | 0 / 7 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 97.1% |
| HHI | 2,509 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $68.86M | 831.65K |
| Citadel Advisors | $45.42M | 35.00M |
| Millennium Management | $41.99M | 507.21K |
| Capital Research / Capital World | $24.63M | 297.54K |
| Renaissance Technologies | $5.27M | 63.70K |
| Fidelity / FMR LLC | $3.05M | 36.85K |
| AQR Capital Management | $2.44M | 29.50K |
| T. Rowe Price Group | $1.42K | 17.10K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $883.37M | +59.7% | |
| Operating income | $584.00K | -35.7% | |
| Net income | -$18.52M | +80.5% | |
| Cash from ops | $64.02M | +12.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $74.00 | $74.97 | $73.30 | $74.00 | 278.70K |
| Sep 24 | $74.00 | $75.50 | $73.69 | $74.04 | 368.80K |
| Sep 23 | $77.00 | $78.86 | $74.21 | $74.43 | 433.60K |
| Sep 22 | $78.49 | $79.32 | $76.58 | $77.91 | 469.60K |
| Sep 21 | $75.50 | $79.43 | $75.00 | $78.85 | 579.30K |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →